The effects of coenzyme Q10 supplementation on cardiometabolic markers in overweight type 2 diabetic patients with stable myocardial infarction: A randomized,double-blind,placebo-controlled trial

Background: limited data are present that have assessed the effects of coenzyme q10 (coq10) intake on cardiometabolic markers in type 2 diabetic patients with coronary heart disease (chd). this study was done to determine the effects of coq10 administration on cardiometabolic markers in overweight diabetic patients with stable myocardial infarction. methods: this randomized double-blind placebo-controlled clinical trial was done among 60 diabetic patients with chd aged 45-75 years old. subjects were randomly allocated into two groups to receive either 100 mg/day coq10 supplements (n = 30) or placebo (n = 30) for 8 weeks. results: compared with the placebo,coq10 intake led to a significant reduction in serum interleukin 6 (il-6) (-1.7 ± 1.6 vs. 0.8 ± 1.7 ng/l,p < 0.001) and protein carbonyl (pco) levels (-0.2 ± 0.3 vs. 0.1 ± 0.2 nmol/mg protein,p < 0.001). supplementation with coq10 did not affect serum lipoprotein(a),advanced glycation end-products and thiol concentrations compared with the placebo. conclusion: overall,this study indicated that coq10 intake after 8 weeks among diabetic patients with the stable chd had beneficial effects on serum il-6 and pco levels,but did not alter other cardiometabolic markers. © 2016,isfahan university of medical sciences(iums). all rights reserved.